Contributions
Abstract: PB1551
Type: Publication Only
Session title: Hodgkin lymphoma - Clinical
Background
Bleomycin is a major antimitotic agent in the first-line treatment for Hodgkin's lymphoma. The main limitation of its use is its pulmonary toxicity.
Aims
The objectives of this study are to find out the risk factors for the occurrence of bleomycin-induced lung toxicity in patients with Hodgkin's lymphoma, on the other hand to determine if positron emission tomography scan is a reliable means of early detection of this toxicity.
Methods
This is a retrospective study conducted in the clinical haematology department of Mohammed V Military Instruction Hospital of Rabat in Morocco. All patients with Hodgkin's lymphoma and treated with a bleomycin based chemotherapy were included.
Results
Among 124 patients included in the study, 18 (14.5%) patients experienced bleomycin-induced lung toxicity. On multivariate analysis, smoking (p: 0.038) and the use of the ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) compared to the escalated BEACOPPe (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) regimen (p: 0.018) were statistically significant risk factors.
After 2 and 4 courses of therapy, the positron emission tomography was able to predict the occurrence of bleomycin-induced lung toxicity before the appearance of clinical symptoms in 43.7 % and 12.5% of patients, respectively.
Conclusion
Researches to identify risk factors for the development of bleomycin-induced lung toxicity are crucial to reduce toxicity in the treatment of Hodgkin's lymphoma. However, 2- and 4-cycles positron emission tomography scans cannot be considered as a reliable means of early detection of this toxicity.
Keyword(s): Chemotherapy, Hodgkin's lymphoma, Lung, Toxicity
Abstract: PB1551
Type: Publication Only
Session title: Hodgkin lymphoma - Clinical
Background
Bleomycin is a major antimitotic agent in the first-line treatment for Hodgkin's lymphoma. The main limitation of its use is its pulmonary toxicity.
Aims
The objectives of this study are to find out the risk factors for the occurrence of bleomycin-induced lung toxicity in patients with Hodgkin's lymphoma, on the other hand to determine if positron emission tomography scan is a reliable means of early detection of this toxicity.
Methods
This is a retrospective study conducted in the clinical haematology department of Mohammed V Military Instruction Hospital of Rabat in Morocco. All patients with Hodgkin's lymphoma and treated with a bleomycin based chemotherapy were included.
Results
Among 124 patients included in the study, 18 (14.5%) patients experienced bleomycin-induced lung toxicity. On multivariate analysis, smoking (p: 0.038) and the use of the ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) compared to the escalated BEACOPPe (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) regimen (p: 0.018) were statistically significant risk factors.
After 2 and 4 courses of therapy, the positron emission tomography was able to predict the occurrence of bleomycin-induced lung toxicity before the appearance of clinical symptoms in 43.7 % and 12.5% of patients, respectively.
Conclusion
Researches to identify risk factors for the development of bleomycin-induced lung toxicity are crucial to reduce toxicity in the treatment of Hodgkin's lymphoma. However, 2- and 4-cycles positron emission tomography scans cannot be considered as a reliable means of early detection of this toxicity.
Keyword(s): Chemotherapy, Hodgkin's lymphoma, Lung, Toxicity